Joel Pearlman
Retina Specialist · Sacramento, CANPI 1154430460
Payments from drug & device makers
Across 1,406 payments — averaging $5915.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$4.1M
- Roche TCRC, Inc.$838K
- Boehringer Ingelheim$812K
- Regeneron$692K
- Eyepoint US, Inc.$555K
- Apellis Pharmaceuticals, Inc.$393K
- plus $934K from 27 others
Across 4 payments — averaging $33.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$136
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 360 | $4,092,208 |
| Roche TCRC, Inc. | 71 | $837,527 |
| Boehringer Ingelheim | 41 | $812,370 |
| Regeneron | 347 | $692,051 |
| Eyepoint US, Inc. | 5 | $555,406 |
| Apellis Pharmaceuticals, Inc. | 157 | $393,361 |
| Bayer | 37 | $285,994 |
| Amgen | 19 | $252,409 |
| Boehringer Ingelheim International GmbH | 248 | $208,378 |
| Hexal AG | 19 | $80,733 |
| GSK | 10 | $69,813 |
| Astellas Pharma Global Development | 5 | $11,976 |
| AbbVie | 6 | $8,277 |
| Hoffmann-la Roche Limited | 3 | $4,880 |
| Genentech USA, Inc. | 19 | $2,849 |
| Ocular Therapeutix, Inc. | 1 | $1,600 |
| Alcon | 6 | $1,536 |
| Boehringer Ingelheim Finland Ky | 8 | $1,186 |
| Carl Zeiss Meditec USA, Inc. | 1 | $840 |
| Carl Zeiss Meditec, Inc. | 2 | $720 |
| Regeneron Healthcare Solutions, Inc. | 10 | $689 |
| Alcon Research LLC | 1 | $490 |
| Topcon Healthcare, Inc. | 6 | $348 |
| Biotissue Holdings Inc. | 4 | $346 |
| Astellas Pharma US Inc | 5 | $322 |
| Novartis | 5 | $272 |
| Harrow Eye, LLC | 1 | $119 |
| Alimera Sciences, Inc. | 3 | $66 |
| Biogen | 2 | $45 |
| Dutch Ophthalmic, USA | 1 | $45 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $21 |
| Notal Vision, Inc. | 1 | $13 |
How this compares
$8,316,913 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Sacramento
- Margaret ChangSacramento$13.2M
- David TelanderSacramento$780K
- Glenn YiuSacramento$668K
- Carlos Medina MendezSacramento$548K
- Dante PieramiciSanta Barbara$15.1M
- Hani Salehi-HadHuntington Beach$12.2M
- Payam AminiPasadena$9.9M
- Dilsher DhootSanta Barbara$8.2M
- Ashkan PirouzFullerton$6.9M
- Roger GoldbergWalnut Creek$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.